GlassScriptPhysician profile
Jaideep Dasgupta
NPI 1871989228
$13,274.89
in general payments reported to CMS, 2019-2025
18 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $1,700 · 2021: $402 · 2022: $5,090 · 2023: $2,329 · 2024: $2,050 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,405 · Food and Beverage: $2,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,405.20 |
| Food and Beverage | $2,554.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $5,516.44 | 2020-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis |
| Medtronic, INC. | $3,041.09 | 2022-2025 | Turbohawk, Endurant Iis, Venaseal |
| Silk Road Medical, INC. | $2,971.97 | 2020-2022 | |
| Medtronic Vascular, INC. | $375.00 | 2020 | |
| Boston Scientific Corporation | $217.07 | 2022 | |
| Bolton Medical INC | $191.98 | 2021 | |
| Philips North America LLC | $179.83 | 2022-2024 | (P77) Azurion 7 M20 |
| Novartis Pharmaceuticals Corporation | $152.56 | 2023-2024 | |
| Endologix LLC | $126.84 | 2020 | |
| Allergan, INC. | $123.19 | 2019 | |
| Terumo Medical Corporation | $112.00 | 2021 | |
| Cardiva Medical, INC. | $105.25 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $43.40 | 2024-2025 | Winrevair, Verquvo |
| Stryker Corporation | $42.04 | 2025 | Artix Mt, Flowtriever |
| Actelion Pharmaceuticals US, INC. | $30.03 | 2024-2025 | Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.20 | 2025 | Camzyos |
| Amgen INC. | $15.99 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $14.01 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaideep Dasgupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.